SCHEMBL5144989

SCHEMBL5144989

O=C1N/C(=C/c2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)C(=O)N1c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.70
KMT2A Q03164 12/20 0.70
MEN1 O00255 11/20 0.70
POLB P06746 10/20 0.70
TDP1 Q9NUW8 10/20 0.70
KDM4E B2RXH2 9/20 0.70
RECQL P46063 6/20 0.70
L3MBTL1 Q9Y468 4/20 0.70
CTDSP1 Q9GZU7 4/20 0.70
APEX1 P27695 4/20 0.70
PTPN1 P18031 1/20 0.70
ALDH1A1 P00352 10/20 0.61
LMNA P02545 4/20 0.52
PKM P14618 4/20 0.52
RAB9A P51151 2/20 0.52
GAA P10253 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 2/20 0.50
DNMT1 P26358 2/20 0.50
PSMD14 O00487 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145006 1.00 MAPT (0.70) MAPTKMT2AMEN1POLBTDP1
SCHEMBL5163450 0.77 GSK3A (0.74) MAPTKMT2AMEN1POLBTDP1
SCHEMBL5163453 0.77 GSK3A (0.74) MAPTKMT2AMEN1POLBTDP1
SCHEMBL6397402 0.76 KMT2A (0.87) MAPTKMT2AMEN1POLBTDP1
SCHEMBL6397406 0.76 KMT2A (0.87) MAPTKMT2AMEN1POLBTDP1
SCHEMBL31358797 0.75 KMT2A (0.56) MAPTKMT2AMEN1POLBTDP1
SCHEMBL6395650 0.74 TDP1 (0.75) MAPTKMT2AMEN1POLBTDP1
SCHEMBL6395653 0.74 TDP1 (0.75) MAPTKMT2AMEN1POLBTDP1
SCHEMBL5166948 0.73 MAPT (0.54) MAPTKMT2AMEN1POLBTDP1
SCHEMBL5166946 0.73 MAPT (0.54) MAPTKMT2AMEN1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MAPT 2096/4885KMT2A 4410/4885MEN1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.